Dupixent global net sales rose 35% to $6.5B in 3Q
Sanofi-recorded global net sales for Dupixent rose 35% to $6.5 billion in the third quarter.
Related stories
RBC Says DexCom Q3 Results and Higher Revenue Guidance Point to Stronger 2027
MT Newswires reports that DexCom posted better-than-expected Q3 results and higher revenue guidance; RBC says the results point to a stronger 2027.
M impact | EQUITY | Oct 30, 2026, 03:53 PM UTC
UniCredit Sets Nov. 1 Effective Date for Merger With UniCredit SA/NV
UniCredit SA/NV will merge effective Nov. 1.
M impact | EQUITY | Oct 30, 2026, 03:52 PM UTC
Euronext Dublin Issues Delisting Notice for Octagon Loan Funding
Euronext Dublin issued a delisting notice for Octagon Loan Funding, Ltd.
M impact | EQUITY | Oct 30, 2026, 03:47 PM UTC
HSBC Upgrades GE Vernova to Buy, Citing Power Equipment Demand
HSBC analyst Sean McLoughlin upgraded GE Vernova to Buy from Hold, citing higher pricing and profit margins tied to strong demand for power-generating equipment.
H impact | EQUITY | Oct 30, 2026, 03:46 PM UTC
ExxonMobil CEO Says Company Focused on Diesel Production
CEO Darren Woods said ExxonMobil is focused on producing diesel, which he described as a key supply crunch point amid rising fuel prices and geopolitical tensions.
M impact | EQUITY | Oct 30, 2026, 03:45 PM UTC
AstraZeneca reports 23% third-quarter profit growth
AstraZeneca reported a 23% increase in profit in the third quarter.
M impact | EQUITY | Oct 30, 2026, 03:43 PM UTC